{"id":32683,"date":"2025-04-29T14:45:46","date_gmt":"2025-04-29T06:45:46","guid":{"rendered":"https:\/\/flcube.com\/?p=32683"},"modified":"2025-04-29T14:45:47","modified_gmt":"2025-04-29T06:45:47","slug":"johnson-johnsons-tar-200-shows-promising-results-in-phase-iib-sunrise-1-study-for-bladder-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32683","title":{"rendered":"Johnson &amp; Johnson&#8217;s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer"},"content":{"rendered":"\n<p>US giant Johnson &amp; Johnson (J&amp;J; <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) has released the first results from Cohort 4 of the Phase IIb SunRISe-1 study, assessing TAR-200, an intravesical gemcitabine releasing system, in patients with certain types of bladder cancer. Preliminary findings indicate that TAR-200 achieved a disease-free survival rate (DFS) of over 80%, with no reinduction required and 94% of patients able to preserve their bladder. In patients with Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with papillary-only disease (high-grade Ta or T1), TAR-200\u2019s high DFS and bladder preservation rate, combined with its well-tolerated safety profile, highlight its potential as a meaningful alternative to surgery.<\/p>\n\n\n\n<p><strong>Safety Profile and Adverse Events<\/strong><br>Among the 52 patients enrolled in the study, TAR-200 monotherapy demonstrated a safety profile consistent with prior studies, with no new safety signals observed. Most treatment-related adverse events (TRAEs) were low grade and resolved quickly, with a median duration of 3.7 weeks. Common TRAEs included dysuria (40.4%), pollakiuria (30.8%), and urgency (26.9%). Grade \u22653 TRAEs occurred in 13.5% of patients, most frequently bladder pain (3.8%). Three patients (5.8%) experienced serious TRAEs, and only four (7.7%) discontinued treatment due to TRAEs. Importantly, no treatment-related deaths were reported.<\/p>\n\n\n\n<p><strong>Regulatory Milestones<\/strong><br>TAR-200, an investigational intravesical gemcitabine releasing system, was filed for marketing in the US in January of this year. The drug was awarded Breakthrough Therapy Designation (BTD) in December 2023 for the treatment of adult patients with BCG-unresponsive HR-NMIBC with carcinoma in situ (CIS) who are ineligible for or have elected not to undergo radical cystectomy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US giant Johnson &amp; Johnson (J&amp;J; NYSE: JNJ) has released the first results from Cohort&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32684,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,17,150,149,858],"class_list":["post-32683","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-results","tag-jj","tag-johnson-johnson","tag-nyse-jnj"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Johnson &amp; Johnson&#039;s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US giant Johnson &amp; Johnson (J&amp;J; NYSE: JNJ) has released the first results from Cohort 4 of the Phase IIb SunRISe-1 study, assessing TAR-200, an intravesical gemcitabine releasing system, in patients with certain types of bladder cancer. Preliminary findings indicate that TAR-200 achieved a disease-free survival rate (DFS) of over 80%, with no reinduction required and 94% of patients able to preserve their bladder. In patients with Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with papillary-only disease (high-grade Ta or T1), TAR-200\u2019s high DFS and bladder preservation rate, combined with its well-tolerated safety profile, highlight its potential as a meaningful alternative to surgery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32683\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson &amp; Johnson&#039;s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer\" \/>\n<meta property=\"og:description\" content=\"US giant Johnson &amp; Johnson (J&amp;J; NYSE: JNJ) has released the first results from Cohort 4 of the Phase IIb SunRISe-1 study, assessing TAR-200, an intravesical gemcitabine releasing system, in patients with certain types of bladder cancer. Preliminary findings indicate that TAR-200 achieved a disease-free survival rate (DFS) of over 80%, with no reinduction required and 94% of patients able to preserve their bladder. In patients with Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with papillary-only disease (high-grade Ta or T1), TAR-200\u2019s high DFS and bladder preservation rate, combined with its well-tolerated safety profile, highlight its potential as a meaningful alternative to surgery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32683\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-29T06:45:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-29T06:45:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2911.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32683#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32683\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Johnson &amp; Johnson&#8217;s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer\",\"datePublished\":\"2025-04-29T06:45:46+00:00\",\"dateModified\":\"2025-04-29T06:45:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32683\"},\"wordCount\":264,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32683#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2911.webp\",\"keywords\":[\"Cancer\",\"Clinical trial results\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32683#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32683\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32683\",\"name\":\"Johnson &amp; Johnson's TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32683#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32683#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2911.webp\",\"datePublished\":\"2025-04-29T06:45:46+00:00\",\"dateModified\":\"2025-04-29T06:45:47+00:00\",\"description\":\"US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort 4 of the Phase IIb SunRISe-1 study, assessing TAR-200, an intravesical gemcitabine releasing system, in patients with certain types of bladder cancer. Preliminary findings indicate that TAR-200 achieved a disease-free survival rate (DFS) of over 80%, with no reinduction required and 94% of patients able to preserve their bladder. In patients with Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with papillary-only disease (high-grade Ta or T1), TAR-200\u2019s high DFS and bladder preservation rate, combined with its well-tolerated safety profile, highlight its potential as a meaningful alternative to surgery.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32683#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32683\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32683#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2911.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2911.webp\",\"width\":1080,\"height\":608,\"caption\":\"Johnson & Johnson's TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32683#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson &amp; Johnson&#8217;s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Johnson &amp; Johnson's TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort 4 of the Phase IIb SunRISe-1 study, assessing TAR-200, an intravesical gemcitabine releasing system, in patients with certain types of bladder cancer. Preliminary findings indicate that TAR-200 achieved a disease-free survival rate (DFS) of over 80%, with no reinduction required and 94% of patients able to preserve their bladder. In patients with Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with papillary-only disease (high-grade Ta or T1), TAR-200\u2019s high DFS and bladder preservation rate, combined with its well-tolerated safety profile, highlight its potential as a meaningful alternative to surgery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32683","og_locale":"en_US","og_type":"article","og_title":"Johnson &amp; Johnson's TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer","og_description":"US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort 4 of the Phase IIb SunRISe-1 study, assessing TAR-200, an intravesical gemcitabine releasing system, in patients with certain types of bladder cancer. Preliminary findings indicate that TAR-200 achieved a disease-free survival rate (DFS) of over 80%, with no reinduction required and 94% of patients able to preserve their bladder. In patients with Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with papillary-only disease (high-grade Ta or T1), TAR-200\u2019s high DFS and bladder preservation rate, combined with its well-tolerated safety profile, highlight its potential as a meaningful alternative to surgery.","og_url":"https:\/\/flcube.com\/?p=32683","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-29T06:45:46+00:00","article_modified_time":"2025-04-29T06:45:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2911.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32683#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32683"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Johnson &amp; Johnson&#8217;s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer","datePublished":"2025-04-29T06:45:46+00:00","dateModified":"2025-04-29T06:45:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32683"},"wordCount":264,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32683#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2911.webp","keywords":["Cancer","Clinical trial results","J&amp;J","Johnson &amp; Johnson","NYSE: JNJ"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32683#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32683","url":"https:\/\/flcube.com\/?p=32683","name":"Johnson &amp; Johnson's TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32683#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32683#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2911.webp","datePublished":"2025-04-29T06:45:46+00:00","dateModified":"2025-04-29T06:45:47+00:00","description":"US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort 4 of the Phase IIb SunRISe-1 study, assessing TAR-200, an intravesical gemcitabine releasing system, in patients with certain types of bladder cancer. Preliminary findings indicate that TAR-200 achieved a disease-free survival rate (DFS) of over 80%, with no reinduction required and 94% of patients able to preserve their bladder. In patients with Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with papillary-only disease (high-grade Ta or T1), TAR-200\u2019s high DFS and bladder preservation rate, combined with its well-tolerated safety profile, highlight its potential as a meaningful alternative to surgery.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32683#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32683"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32683#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2911.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2911.webp","width":1080,"height":608,"caption":"Johnson & Johnson's TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32683#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Johnson &amp; Johnson&#8217;s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2911.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32683"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32683\/revisions"}],"predecessor-version":[{"id":32685,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32683\/revisions\/32685"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32684"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}